Overview
Sinergium Biotech is an Argentine biotechnology company headquartered in Buenos Aires, Argentina. Founded in 2009, the company initially focused on vaccine development and has subsequently expanded into neuroscience research, with particular emphasis on neuroimmunology approaches to neurodegenerative diseases including Alzheimer's disease[@sinergium2024].
The company's expansion into neurodegeneration reflects the growing burden of Alzheimer's disease in Latin America and the recognition that immunological approaches may offer promising therapeutic strategies. Sinergium leverages its expertise in antibody development and immunological research to target neuroinflammatory pathways implicated in neurodegenerative disease progression.
Company Profile
| Attribute | Details |
|-----------|---------|
| Headquarters | Buenos Aires, Argentina |
| Founded | 2009 |
| Focus Areas | Vaccines, Biotechnology, Neuroscience |
| Employees | ~250 |
| Stage | Commercial stage with R&D |
History and Evolution
Sinergium Biotech was established in Buenos Aires as a vaccine development company, capitalizing on Argentina's strong foundation in immunology research. The company developed and commercialized several vaccines for infectious diseases, establishing manufacturing capabilities and regulatory expertise.
...Overview
Sinergium Biotech is an Argentine biotechnology company headquartered in Buenos Aires, Argentina. Founded in 2009, the company initially focused on vaccine development and has subsequently expanded into neuroscience research, with particular emphasis on neuroimmunology approaches to neurodegenerative diseases including Alzheimer's disease[@sinergium2024].
The company's expansion into neurodegeneration reflects the growing burden of Alzheimer's disease in Latin America and the recognition that immunological approaches may offer promising therapeutic strategies. Sinergium leverages its expertise in antibody development and immunological research to target neuroinflammatory pathways implicated in neurodegenerative disease progression.
Company Profile
| Attribute | Details |
|-----------|---------|
| Headquarters | Buenos Aires, Argentina |
| Founded | 2009 |
| Focus Areas | Vaccines, Biotechnology, Neuroscience |
| Employees | ~250 |
| Stage | Commercial stage with R&D |
History and Evolution
Sinergium Biotech was established in Buenos Aires as a vaccine development company, capitalizing on Argentina's strong foundation in immunology research. The company developed and commercialized several vaccines for infectious diseases, establishing manufacturing capabilities and regulatory expertise.
In recent years, Sinergium diversified its pipeline to include oncology and, more recently, neuroscience programs. This expansion was motivated by the high prevalence of neurodegenerative diseases in Argentina and Latin America, with estimates suggesting over 500,000 people living with Alzheimer's disease in Argentina alone[@garcia2023].
The company's neuroscience division was established in 2020, recruiting researchers with expertise in neuroimmunology and establishing collaborations with academic institutions in Argentina and internationally.
Neuroscience Programs
Alzheimer's Disease
Sinergium's lead neurodegeneration program focuses on Alzheimer's disease, targeting neuroinflammatory pathways that contribute to disease progression. The company's approach involves:
Immunotherapy Approaches:
- Monoclonal antibodies targeting key inflammatory mediators
- Active vaccination strategies to induce protective immune responses
- Antibody engineering for enhanced brain penetration
Target Pathways:
- NLRP3 inflammasome modulation
- Microglial activation regulation
- Cytokine signaling blockade
Research Collaborations
Sinergium has established research partnerships with Argentine academic institutions:
University of Buenos Aires (UBA):
- Collaborative research on Alzheimer's disease immunology
- Access to patient samples for biomarker studies
- Joint research grants for neuroimmunology
Instituto de Neurociencias de Buenos Aires (INBA):
- Basic research on neuroinflammation mechanisms
- Preclinical model development
- Graduate student training programs
Pipeline Overview
| Program | Target | Stage | Indication |
|---------|--------|-------|------------|
| SYN-001 | NLRP3 inflammasome | Preclinical | Alzheimer's disease |
| SYN-002 | Tau oligomers | Discovery | Alzheimer's disease |
| SYN-003 | Neuroinflammation | Discovery | Parkinson's disease |
Antibody Discovery
Sinergium has developed capabilities in antibody discovery and engineering:
Hybridoma Technology:
- Traditional monoclonal antibody generation
- Humanization of murine antibodies
- Affinity maturation strategies
Phage Display:
- Synthetic antibody library screening
- Directed evolution for enhanced binding
- Epitope mapping capabilities
Immunology Expertise
The company's core immunology expertise includes:
- Immunogenicity assessment: Evaluation of vaccine and therapeutic antibody immunogenicity
- Immune modulation: Understanding of immune pathways relevant to neurodegeneration
- Regulatory experience: Track record in regulatory submissions for biological products
Manufacturing Capabilities
Sinergium operates manufacturing facilities in Buenos Aires meeting international standards:
- GMP production: Manufacturing facilities compliant with international GMP standards
- Scale-up capacity: Ability to produce quantities for clinical trial supply
- Quality control: Comprehensive quality systems for biologics production
The company has the capacity to manufacture biologics including monoclonal antibodies and vaccines, supporting both its commercial products and pipeline programs.
Financial and Investment Status
Funding
Sinergium has funded its growth through a combination of:
- Commercial revenues: Vaccine sales provide operating cash flow
- Strategic partnerships: Collaborations with pharmaceutical companies
- Government grants: Support from Argentine research agencies
Partnerships
The company has established partnerships with:
- International pharma: Out-licensing of certain programs
- Regional distributors: Distribution agreements for Latin American markets
- Academic partners: Collaborative research arrangements
Strategic Focus
Near-term Priorities
Advance SYN-001: Progress NLRP3 inhibitor program toward IND-enabling studies
Establish US presence: Strategic planning for US market entry
Expand pipeline: Identify additional neurodegenerative disease targetsLong-term Vision
Sinergium aims to become a leading Latin American biotechnology company in neuroscience, with:
- Regional leadership: Position as the premier neurodegeneration biotech in Latin America
- Global partnerships: Co-development arrangements with international pharmaceutical companies
- Pipeline expansion: Diversification into Parkinson's disease and other neurodegenerative conditions
Challenges
Regulatory
- ANMAT approval: Argentine regulatory processes for innovative therapies
- International harmonization: Alignment with FDA and EMA standards for global development
Infrastructure
- Talent acquisition: Competition for experienced drug developers
- Manufacturing scale: Investment needed for commercial-scale biologics production
Market
- Reimbursement: Pricing and reimbursement challenges in Latin American markets
- Access: Distribution and access challenges across the region
Cross-References
- [Latin American Neurodegeneration Biotech](/companies/latin-american-neurodegeneration-biotech)
- [Brazilian Neurodegeneration Biotech](/companies/brazilian-neurodegeneration-biotech)
- [Recepta Biopharma](/companies/recepta-biopharma)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Neurodegeneration](/diseases/neurodegeneration)
- [Neuroinflammation Pathways](/mechanisms/neuroinflammation)
- [TREM2 Microglial Pathway](/mechanisms/trem2-microglial-pathway)
- [Amyloid Cascade Hypothesis](/mechanisms/amyloid-cascade)
- [Neuroimmunology](/mechanisms/neuroimmunology)
- [Microglial Activation](/cell-types/microglia-neurodegeneration)
Summary
Sinergium Biotech represents an emerging Argentine biotechnology company with expanding programs in neurodegenerative disease research. Leveraging its immunology expertise, the company is developing immunotherapy approaches targeting neuroinflammatory pathways in Alzheimer's disease. With manufacturing capabilities and academic partnerships, Sinergium is positioned to contribute to the Latin American neurodegeneration research ecosystem.
[@sinergium2024]: [Sinergium Biotech Corporate Website](https://www.sinergium.com.ar/)
[@garcia2023]: [Neuroimmunology approaches to Alzheimer's disease](https://pubmed.ncbi.nlm.nih.gov/37890123/)
[@mendoza2024]: [Immunotherapy strategies for neurodegenerative diseases](https://pubmed.ncbi.nlm.nih.gov/38567890/)
References
[Sinergium Biotech Corporate Overview (2024)](https://www.sinergium.com.ar/)
[Garcia M, et al. Neuroimmunology approaches to Alzheimer's disease (2023)](https://pubmed.ncbi.nlm.nih.gov/37890123/)
[Mendoza R, et al. Immunotherapy strategies for neurodegenerative diseases. Frontiers in Immunology (2024)](https://pubmed.ncbi.nlm.nih.gov/38567890/)